Clinical trials: Hepatic Steatosis
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Liver Injury, Mindray Hepatus 9 Ultrasound Diagnostic System
Multicenter Clinical Study on Noninvasive Assessment of Hepatic Steatosis and Fibrosis Using Visual Transient Elastography
Using liver biopsy as the gold standard, this study will conduct visual transient elastography (ViTE) examinations using Mindray Hepatus 9 ultrasound diagnostic system in patients with liver injury to evaluate the diagnostic…
- Trial name
- NCT07128108
- Testing
- Visual Transient Elastography (ViTE) Examination
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Usefulness of Ultrasound-derived Fat Fraction for Quantification of Hepatic Steatosis in Patients Suspected of MASLD
This study aims to evaluate the diagnostic utility of ultrasound-derived fat fraction (UDFF) in assessing hepatic steatosis in patients with suspected metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT06662851
- Testing
- UDFF
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- So Yeon Kim
Non-Alcoholic Fatty Liver
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an…
- Trial name
- NCT03953456
- Testing
- elafibranor 120mg
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Genfit
Non-Alcoholic Fatty Liver Disease
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease affecting a quarter of the world population. Pathological accumulation of fat, into the hepatocytes, is the first hit and is due to altered hepatic and…
- Trial name
- NAFLD LAL (NCT05419765)
- Testing
- Peripheral blood withdrawn
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- University of Roma La Sapienza
HIV Infections, Hepatitis C
Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty…
- Trial name
- NCT00023218
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- 3 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Disease
Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients
Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver.
- Trial name
- NCT00844779
- Testing
- Bariatric surgery, cholecystectomy or benign liver tumor removal
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Strasbourg, France
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Hepatic Steatosis, Pituitary Gland Failure
Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging
The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population.
- Trial name
- SHAH (NCT02814240)
- Testing
- NMR, Blood samples, fibroscan
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Acute Liver Failure, Mitochondrial Diseases
Longitudinal Study of Mitochondrial Hepatopathies
The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating…
- Conditions
- Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial
- Trial name
- MITOHEP (NCT01148550)
- Where
- 16 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Arbor Research Collaborative for Health
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Non-alcoholic Fatty Liver Disease
Quantitative Detection Efficiency of UDFF for Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting more than 25 % of the population globally.
- Trial name
- UDFF (NCT05802199)
- Testing
- Hepatic fat fraction and hepatic fibrosis
- Where
- 14 sites in China, Switzerland
- Volunteers
- 300 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
EVOO and Metabolic Liver Health in MASLD
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and…
- Trial name
- EvoLiveR (NCT07412444)
- Testing
- Oil Supplementation - 3 tablespoons of oil, 9 Tablespoons of Oil
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
MASH, MASLD
Global Research Initiative for Patients Screening on MASH
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe…
- Conditions
- MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
- Trial name
- GRIPonMASH (NCT05651724)
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 10,000 people
- Sponsor
- Julius Clinical
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
Growth Hormone, Recombinant, Fatty Liver
The Effect of Growth Hormone Replacement on Liver Fat
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.
- Trial name
- NCT00774579
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Obesity, Dyslipidemia
Reduction of Sweetened Beverages and Intrahepatic Fat
The study will enroll 68 overweight male and female subjects with a high (> 2 3dl-can soda/day) consumption of sweetened beverage per day.
- Conditions
- Obesity, Dyslipidemia, Metabolic Syndrome
- Trial name
- REDUCS (NCT01394380)
- Testing
- artificially sweetened sodas
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- University of Lausanne
Chronic Hepatitis
Hepatic Steatosis and Chronic Hepatitis B Virus
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
- Trial name
- NCT05678582
- Testing
- Liver biopsy
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Sohag University
Non-Alcoholic Fatty Liver Disease, Liver Diseases
Treating Pediatric NAFLD with Nutrition
This is a proof of concept clinical trial to compare daily intake of at least 20 grams of whole dairy fat vs habitual diet on hepatic steatosis in children with NAFLD.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis
- Trial name
- NCT05499585
- Testing
- Whole Dairy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic
Fatty Liver and Pancreatic Steatosis
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.
- Conditions
- Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic Steatosis
- Trial name
- NCT06757348
- Testing
- Fecal elastase, Ecoendoscopy, Fibroscan
- Where
- Argentina
- Volunteers
- 61 people
- Sponsor
- Maria Marta Piskorz